Shareholder Alert: Ademi LLP Investigates Whether CohBar, Inc. Has Obtained a Fair Price in Its Transaction With Morphogenesis, Inc.
Shareholder Alert: Ademi LLP Investigates Whether CohBar, Inc. Has Obtained a Fair Price in Its Transaction With Morphogenesis, Inc.
MILWAUKEE, May 24, 2023 /PRNewswire/ -- Ademi LLP is investigating CohBar (NASDAQ: CWBR) for possible breaches of fiduciary duty and other violations of law in its transaction with Morphogenesis, Inc.
密尔沃， 2023年5月24日 /PRNewswire/ — Ademi LLP 正在调查 CohBar（纳斯达克股票代码：CWBR）在与 Morphogenesis, Inc. 的交易中可能违反信托义务和其他违法行为。
Click here to learn how to join the action or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
点击此处了解如何加入行动或致电 Guri Ademi 免费电话 866-264-3995。您无需承担任何费用或义务。
CohBar public stockholders are expected to receive a dividend equal to approximately 3.30 shares of CohBar common stock on or about the effective date of the merger. On a pro forma basis taking into account the concurrent financing described below and the issuance of the stock dividend, pre-merger CohBar equityholders are expected to collectively own approximately 15% and pre-merger Morphogenesis equityholders are expected to collectively own approximately 77%, respectively, of the common stock of CohBar on a pro forma basis. Additionally, pre-merger CohBar stockholders and certain warrant holders of record will receive a contingent value right (CVR). Holders of the CVR will be entitled to receive certain payments from proceeds received by CohBar, if any, related to the disposition of CohBar's legacy mitochondrial assets for a period of three years following the closing of the proposed merger. The transaction agreement unreasonably limits competing bids for CohBar by imposing a significant penalty if CohBar accepts a superior bid. CohBar insiders will receive substantial benefits as part of change of control arrangements.
预计在合并生效之日当天或前后，CohBar公众股东将获得相当于约3.30股CohBar普通股的股息。考虑到下文所述的并行融资和股票分红的发放，预计合并前的CohBar股权持有人将共同拥有约15％，合并前的Morphogenesis股权持有人预计将共同拥有CohBar约77％的普通股。此外，合并前的CohBar股东和某些登记在册的认股权证持有人将获得或有价值权（CVR）。在拟议合并完成后的三年内，CVR的持有人将有权从CohBar收到的与处置CohBar遗留线粒体资产有关的收益（如果有）中获得某些款项。如果CohBar接受更高的出价，该交易协议将处以巨额罚款，从而不合理地限制了对CohBar的竞标。作为控制权变更安排的一部分，CohBar内部人士将获得可观的收益。
We are investigating the conduct of CohBar's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for CohBar.
我们正在调查CohBar董事会的行为，以及他们是否在履行对所有股东的信托义务，以及（ii）为CohBar争取公平合理的价格。
If you own CohBar common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or
如果您拥有 CohBar 普通股并希望获得更多信息，请联系 Guri Ademi 要么在 [电子邮件保护] 或者免费电话：866-264-3995，或
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
我们专门处理涉及收购、合并和全国各地个人股东权利的股东诉讼。欲了解更多信息，请随时致电我们。律师广告。先前的结果并不能保证类似的结果。
Contacts
联系人
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
Ademi LLP
Guri Ademi
免费电话：(866) 264-3995
传真：(414) 482-8001
SOURCE Ademi LLP
来源 Ademi LLP
译文内容由第三方软件翻译。